Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies

Yuqi Wanga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Quan Quana Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Camille Gleasonb Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USAView further author information

Helin Yua Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Lujia Penga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Yanshen Kanga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Ling Jianga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Kailun Wua Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Jie Pana Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Moxiyele Baoa Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Qing Zhua Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Meiqi Yia Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Ming Fanga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Yue Zhenga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Ling Qiuc Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, ChinaView further author information

Bin Xuc Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, ChinaView further author information

Xiang Lic Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, ChinaView further author information

Jinfeng Songc Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, ChinaView further author information

Jiamu Sund Department of Regulatory Affairs CMC, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Zheng Zhanga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Zijun Sua Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Jara Lina Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Yuanyuan Xiea Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

April Xua Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Xiling Songb Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USAView further author information

Chichi Huanga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Zhirong Shena Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Lai Wanga Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaView further author information

Jing Songa Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, ChinaCorrespondence[email protected]
View further author information

Your download is now in progress and you may close this window